Terminated × Has results × Leukemia, Myelogenous, Chronic, BCR-ABL Positive × Clear all FLUBUTBI
Phase 3 Terminated
53 enrolled 11 charts
Ponatinib - Frontline for Chronic Myeloid Leukemia (CML) in Accelerated Phase (AP)
Phase 2 Terminated
51 enrolled 8 charts
Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia
Phase 2 Terminated
25 enrolled 8 charts
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Phase 2 Terminated
31 enrolled 18 charts
Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia
Phase 1/2 Terminated
9 enrolled 11 charts
Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors
Phase 2 Terminated
9 enrolled 11 charts
Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers
Phase 2 Terminated
1 enrolled 11 charts
An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia
Phase 1 Terminated
37 enrolled 14 charts
Imatinib or Nilotinib With Pegylated Interferon-α2b in Chronic Myeloid Leukemia
Phase 2 Terminated
12 enrolled 8 charts
T-cell Depleted Alternative Donor Transplantation
Phase 2 Terminated
53 enrolled 14 charts
Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors
Phase 4 Terminated
163 enrolled 27 charts
OPTIC-2L
Phase 3 Terminated
44 enrolled 22 charts
A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study)
Phase 1/2 Terminated
10 enrolled 28 charts
AFR22
Phase 2 Terminated
19 enrolled 4 charts
MACS0254
Phase 2 Terminated
18 enrolled 12 charts
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase
Phase 2 Terminated
27 enrolled 14 charts
Stem Cell Transplant for Hematological Malignancy
Phase NA Terminated
330 enrolled 25 charts
Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies
Phase 2 Terminated
3 enrolled 17 charts
Cord Blood
Phase 1/2 Terminated
3 enrolled 8 charts
Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases
Phase NA Terminated
2 enrolled 11 charts
MACS1532
Phase 3 Terminated
7 enrolled 4 charts
Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia
Phase 2 Terminated
4 enrolled 13 charts
Post Transplant Donor Lymphocyte Infusion
Phase 2 Terminated
57 enrolled 13 charts
A Study for Patients With Acute Leukemia
Phase 1 Terminated
33 enrolled 18 charts
Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic Phase Chronic Myeloid Leukemia
Phase 2 Terminated
7 enrolled 5 charts
Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and Low-Dose Ara-C
Phase 2 Terminated
117 enrolled 6 charts
Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)
Phase 2 Terminated
5 enrolled 3 charts
Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers
Phase 2 Terminated
15 enrolled 8 charts
Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells
Phase 1/2 Terminated
10 enrolled 13 charts
Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation
Terminated
56 enrolled 12 charts
Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients
Phase 2 Terminated
5 enrolled 10 charts
Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies
Phase 2 Terminated
9 enrolled 13 charts
Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
Phase 2 Terminated
12 enrolled 12 charts
ENESTswift
Phase 3 Terminated
20 enrolled 17 charts
Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease
Phase 2 Terminated
13 enrolled 24 charts
Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation
Phase 2 Terminated
12 enrolled 12 charts
Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
Phase 2 Terminated
14 enrolled 7 charts
T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant
Phase 2 Terminated
34 enrolled 12 charts
Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB)
Phase 1/2 Terminated
4 enrolled 8 charts
Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia
Phase 2 Terminated
24 enrolled 6 charts
Nuvigil in Treatment of Cancer-Related Fatigue in Chronic Myeloid Leukemia Patients
Phase NA Terminated
1 enrolled 2 charts
Growth Factor Signature (GFS) Pilot Study (MK0000-098)(COMPLETED)
Phase 1 Terminated
9 enrolled 5 charts
Prophylactic White Cell Transfusions Versus Therapeutic White Cell Transfusions in Patients With Leukemia
Phase 2 Terminated
5 enrolled 4 charts
Pegasys in Patients With Chronic Myeloid Leukemia (CML)
Phase 2 Terminated
2 enrolled 3 charts
Haploid Allogeneic Transplant Using the CliniMACS System
Phase 2 Terminated
13 enrolled 7 charts
Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)
Phase 2 Terminated
15 enrolled 6 charts
Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)
Phase 3 Terminated
307 enrolled 11 charts
In-Vivo Activated T-Cell Depletion to Prevent GVHD
Phase NA Terminated
10 enrolled 11 charts
TALL-104 and Gleevec in Chronic Myelogenous Leukemia Patients
Phase 2 Terminated
3 enrolled 6 charts
Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib
Phase 2 Terminated
52 enrolled 8 charts